Date: 2013-01-09
Type of information: R&D agreement
Compound: novel exploratory drug targets and compounds
Company: Evotec (Germany) Yale University (USA)
Therapeutic area: Metabolic diseases - CNS diseases - Immunological diseases - Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: metabolic diseases, CNS diseases, immunological diseases, cancer, glioblastoma
Details: * On January 9, 2013, Evotec has entered into a strategic partnership with Yale University. Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec´s drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially, Evotec and Yale have defined a wide range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds. The intention is to seamlessly integrate Evotec’s drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialised.
Financial terms: Financial details were not disclosed.
Latest news: * On December 17, 2013, Evotec has announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration is to identify novel mechanisms, targets and compounds that have the potential to interfere with DNA repair. TargetDBR is based on systematic cell screens designed to identify DNA repair inhibitors and their mechanisms of action. The application of Evotec’s high-content cellular screening platforms allied to chemoproteomics-based target deconvolution will enable the identification not only of novel DNA repair inhibitors but also of novel tractable targets in DNA repair pathways. The initial focus will be on increasing the effectiveness of glioblastoma brain tumour treatments but it is expected that the DNA repair inhibitors will also find application in many other cancer types. Yale and Evotec will collaborate in a highly integrated fashion and share potential commercial rewards. This is the first collaboration to be announced as part of Evotec’s open innovation alliance with Yale University.
